References
- Duthie SJ, Narayanan S, Sharp L, Little J, Basten G, Powers H. Folate, DNA stability and colo-rectal neoplasia. Proc Nutr Soc. 2004; 63: 571–8
- Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med. 2001; 138: 164–76
- Talley NJ, Chute CG, Larson DE, Epstein R, Lydick EG, Melton LJ 3rd. Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. Ann Intern Med. 1989; 111: 738–42
- Prinz-Langenohl R, Fohr I, Pietrzik K. Beneficial role for folate in the prevention of colorectal and breast cancer. Eur J Nutr. 2001; 40: 98–105
- Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med. 1998; 129: 517–24
- Kim YI. Will mandatory folic acid fortification prevent or promote cancer?. Am J Clin Nutr. 2004; 80: 1123–8
- Midgley R, Kerr DJ. Capecitabine: have we got the dose right?. Nat Clin Pract Oncol. 2009; 6: 17–24
- Bunn, P, Paoletti, P, Niyikiza, C, Rusthoven, J, Nelson, K, Hanauske, AR, , et al. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, Ly231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol. 2001;20: 76a (abstr 300).
- Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit KM, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol. 2008; 19: 909–14
- Bjorkegren K, Svardsudd K. Serum cobalamin, folate, methylmalonic acid and total homocysteine as vitamin B12 and folate tissue deficiency markers amongst elderly Swedes—a population-based study. J Intern Med. 2001; 249: 423–32
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205–16
- Glimelius B. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Ann Oncol. 1993; 4: 235–41
- de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997; 15: 808–15
- Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol. 2002; 13: 1868–73
- Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041–7
- National Cancer Institute. National Cancer Institute common toxicity criteria. Available at: http://ctep.cancer.gov/reporting/ctc.html.
- Calvert H. Folate status and the safety profile of antifolates. Semin Oncol. 2002; 29: 3–7
- Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002; 1: 545–52
- van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, et al. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res. 2001; 61: 3675–81
- Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988; 6: 1653–64
- Ho C, Ng K, O'Reilly S, Gill S. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer. 2005; 5: 279–82
- Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer. 2006; 94: 964–8
- Lokich J. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. Cancer Invest. 2004; 22: 713–7